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Fluoroquinolone (FQ)-associated tendinopathy and myopathy are uncommon but well rec-
ognized complications of the use of this class of antibacterial agents. The case of a
63-year-old previously asymptomatic female patient who developed severe left shoulder
tendinopathy after surreptitiously doubling the prescribed dose of levoﬂoxacin for the treat-
ment of community-acquired pneumonia is reported here. Surgical stabilizationwith suture
anchors and subacromial decompression were needed.luoroquinolone
evoﬂoxacin
endinitis
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luoroquinolone (FQ)-associated tendinopathy, including ten-
on rupture, myopathy, and arthropathy, is an uncommon but
otentially devastating complication of this class of antibacte-
ial agents. It has been described with most representatives of
he class, but oﬂoxacin and ciproﬂoxacin seem to be the most
ommonagents. Symptomsof tendon injury are reported after
median of eight days of initiation of treatment, but they
ay appear as early as two hours after the ﬁrst dose and
s late as six months after treatment.1 The ﬁrst published
ase report was of a 56-year-old renal transplant patient from
ew Zealand, in 1983, who developed Achilles tendinopathy
fter being treated with norﬂoxacin for urinary tract infection
nd septicemia.2 The Achilles tendon is the most commonly
ffected, but any tendon appears to be vulnerable, includ-
ng tendinitis of extraocular muscles leading to diplopia.3
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Este é um artigo Open Access sob a licençaThe case of a female patient who developed severe shoul-
der tendinopathy after surreptitiously doubling the prescribed
dose of a FQ agent for the treatment of community-acquired
pneumonia is reported here.
Case presentation
A previously asymptomatic 63-year-old female patient from
the city of Rio de Janeiro presented with fever, malaise, rigors,
and a productive cough of one-week duration. She reported
that these signs and symptoms developed soon after return-
ing from a weekend trip to a rural area in the highlands of the
state of Rio de Janeiro, where she was exposed to cold weather
during outdoor activities. Physical examination showed anée e Guinle, Rua Mariz e Barros, 775, Rio de Janeiro, RJ, 20270-004,
acutely ill febrile patient (38.5 ◦C) with coarse crackles on aus-
cultation of the left hemithorax. Shewas an otherwise healthy
elderly patient who reported being physically active through
 de CC BY-NC-ND
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Fig. 1 – T2-weighted MRI study of the left shoulder
performed three months after levoﬂoxacin exposure shows
a supraspinatus tendon tear (arrow), corresponding to a
40%-50% thinning, near its insertion on the greater
r
clinical practice. Br J Sports Med. 1997;31:285–98.tuberosity of the humerus.
daily regular aerobic and anaerobic activity at a gym. A chest
x-ray study showed ill-deﬁned patchy airspace inﬁltrates in
the lingular portion of the left upper lobe, consistent with the
diagnosis of acute lower respiratory tract infection. A decision
was made to empirically initiate an outpatient treatment with
levoﬂoxacin 500mg orally once a day for 10 days.
Two weeks later the patient presented with abrupt onset of
diffuse myalgia and severe left shoulder pain. She also com-
plained of pain in the right shoulder, biceps brachii, elbow,
bilateral patellar tendon, and hip. Left shoulder swelling and
pain on palpation were evident on examination. She informed
that the prescribed dose of levoﬂoxacin had been surrepti-
tiously doubled to 500mg bid due to the persistence of fever
as of the second treatment day. Laboratory evaluation was
remarkable for increased creatine phosphokinase (488U/L;
normal value <167U/L). A magnetic resonance imaging (MRI)
study of the left shoulder rotator cuff performed one week
later showed areas of increased T2 signal intensity on sub-
scapular and supraspinatus tendons and a large gleno-umeral
joint effusion with distension of the articular bursa.
The patient was treated with strict physical rest, nons-
teroidal anti-inﬂammatory agents, shoulder splinting for joint
stabilization, and physiotherapy. She gradually improved over
the ensuing weeks, except for the left shoulder pain. An
MRI study performed three months later showed a partial
tear (40%–50% thinning) of the left supraspinatus tendon
(Fig. 1). Surgical intervention was then indicated. Arthroscopy
exploration revealed a rotator cuff injury with subacromial
impingement. Arthroscopic stabilization with suture anchors
and subacromial decompression was performed successfully.
The patient remains well six months after surgical interven-
tion.
DiscussionIn spite of the FDA warning alert released in August 2008,4
FQ-associated tendinopathy and tendon rupture seem not to
be widely known among health care professionals. Proposed12;16(4):393–395
pathogenic mechanisms include a direct toxic effect5 and
ischemic injury.6 FQ toxicity also includes damage to carti-
lage,muscle, and bone tissue.7 It has also been associatedwith
acute severe myalgia requiring emergency care treatment.8
In children and pregnant women, the use of FQs is avoided
since these agents can cause lesions of articular-epiphyseal
cartilage complexes in several species of juvenile animals.9
Major risk factors for FQ-induced tendinopathy include age
over 60, concurrent corticosteroid use, high FQ dose, previous
musculoskeletal disease, renal failure, and diabetes mellitus.
Immediate discontinuation of FQ is warranted, but lack of
knowledge on this syndrome has led to inappropriate advice
to complete the antibacterial course.10 Van der Linden et al.11
have found that approximately 2% to 6% of all Achilles tendon
ruptures in people older than 60 years can be attributed to FQ
use. Imaging studies such as ultrasound and MRI are useful in
identifying tendon tears.
The present case report highlights the importance of judi-
cious use of FQ agents among those with risk factors for
FQ-related tendinopathy, especially older patients. The poten-
tial beneﬁts and risks of prescribing a FQ agent should be
weighed individually. Patients receiving a FQ agent should be
advised to seekmedical attention as soon as any sign or symp-
tom of tendinopathy or myopathy develops. The offending
drug should be immediately withdrawn and measures of joint
rest and expert orthopedic advice instituted. It is also impor-
tant to avoid corticosteroids since these drugsmayworsen the
tendinopathy.
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